Evecxia Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Evecxia Therapeutics General Information

Description

Operator of a biotechnology platform intended to develop therapies for neuropsychiatric disorders through serotonin amplification. The company offers oral tablet technology that supports sustained plasma levels of 5-HTP and prolonged brain serotonin synthesis, enabling physicians and healthcare providers to treat neuropsychiatric conditions with scalable antidepressant augmentation pharmacology.

Contact Information

Website
www.evecxia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • First Flight Venture Center, 2 Davis Drive
  • PO Box 13169, Research Triangle Park
  • Durham, NC 27709
  • United States
+1 (919)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • First Flight Venture Center, 2 Davis Drive
  • PO Box 13169, Research Triangle Park
  • Durham, NC 27709
  • United States
+1 (919)

Evecxia Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evecxia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC Completed Clinical Trials - Phase 1
5. Later Stage VC 16-Sep-2025 Completed Clinical Trials - Phase 1
4. Later Stage VC 01-Feb-2025 Completed Clinical Trials - Phase 1
3. Later Stage VC 20-Aug-2022 Completed Clinical Trials - Phase 1
2. Later Stage VC 09-Nov-2020 $8.5M $9M Completed Clinical Trials - Phase 1
1. Seed Round 01-Jan-2016 $500K $500K Completed Clinical Trials - Phase 1
To view Evecxia Therapeutics’s complete valuation and funding history, request access »

Evecxia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Evecxia Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Evecxia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to develop therapies for neuropsychiatric disorders through serotonin ampl
Drug Discovery
Durham, NC
2 As of 2025

New York, NY
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evecxia Therapeutics Competitors (9)

One of Evecxia Therapeutics’s 9 competitors is AtaiBeckley, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AtaiBeckley Formerly VC-backed New York, NY
Autobahn Therapeutics Venture Capital-Backed San Diego, CA
Neurocrine Biosciences Formerly VC-backed San Diego, CA
Definium Therapeutics Formerly VC-backed New York, NY
Xenon Pharmaceuticals Formerly VC-backed Burnaby, Canada
You’re viewing 5 of 9 competitors. Get the full list »

Evecxia Therapeutics Patents

Evecxia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024148354-A1 A method of enhancing 5-hydroxytryptophan (5-htp) exposure Inactive 06-Jan-2023
EP-4392031-A1 A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes Pending 14-Oct-2021
EP-4392031-A4 A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes Pending 14-Oct-2021
WO-2023064598-A1 A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes Inactive 14-Oct-2021
US-11779567-B2 Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes Active 14-Oct-2021 A61K31/405
To view Evecxia Therapeutics’s complete patent history, request access »

Evecxia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evecxia Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Collage Venture Partners Venture Capital Minority
Bull City Venture Partners Venture Capital Minority
To view Evecxia Therapeutics’s complete investors history, request access »

Evecxia Therapeutics FAQs

  • When was Evecxia Therapeutics founded?

    Evecxia Therapeutics was founded in 2013.

  • Where is Evecxia Therapeutics headquartered?

    Evecxia Therapeutics is headquartered in Durham, NC.

  • What is the size of Evecxia Therapeutics?

    Evecxia Therapeutics has 2 total employees.

  • What industry is Evecxia Therapeutics in?

    Evecxia Therapeutics’s primary industry is Drug Discovery.

  • Is Evecxia Therapeutics a private or public company?

    Evecxia Therapeutics is a Private company.

  • What is Evecxia Therapeutics’s current revenue?

    The current revenue for Evecxia Therapeutics is .

  • How much funding has Evecxia Therapeutics raised over time?

    Evecxia Therapeutics has raised $32M.

  • Who are Evecxia Therapeutics’s investors?

    Collage Venture Partners and Bull City Venture Partners have invested in Evecxia Therapeutics.

  • Who are Evecxia Therapeutics’s competitors?

    AtaiBeckley, Autobahn Therapeutics, Neurocrine Biosciences, Definium Therapeutics, and Xenon Pharmaceuticals are some of the 9 competitors of Evecxia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process